News|Articles|November 20, 2026

Daraxonrasib Plus Gemcitabine/Nab-Paclitaxel Generates Durable Responses in First-Line Metastatic PDAC

Fact checked by: Chris Ryan
Listen
0:00 / 0:00

Key Takeaways

  • Updated RMC-GI-102 subprotocol C results showed ORR 60.7%, DCR 90.2%, median PFS 12.8 months, and 11.1-month median DOR with daraxonrasib + GnP in first-line mPDAC.
  • Deep responses were observed, including 8.2% complete responses, alongside an estimated 76.6% 12-month OS, suggesting a potentially meaningful survival signal for a chemotherapy backbone.
SHOW MORE

Daraxonrasib plus gemcitabine/nab-paclitaxel yielded a 60.7% ORR and 12.8-month median PFS in first-line metastatic pancreatic adenocarcinoma.

First-line daraxonrasib (Rasonque) plus gemcitabine and nab-paclitaxel (Abraxane) produced a durable responses and a median progression-free survival (PFS) exceeding 1 year in patients with treatment-naive metastatic pancreatic adenocarcinoma (mPDAC), according to updated data from the phase 1/2 RMC-GI-102 trial (NCT06445062) presented at the 2026 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.¹,²

The update adds patients and follow-up to data first presented at the 2026 AACR Annual Meeting, and the combination is now being compared with gemcitabine and nab-paclitaxel alone in the phase 3 RASolute 303 trial (NCT07491445).1,3

Updated findings showed that as of a September 28, 2026, data cutoff, patients in the first-line mPDAC cohort (n = 61) had received daraxonrasib at 200 mg plus gemcitabine and nab-paclitaxel, with a median follow-up of 18.3 months (range, 13.1-23.7).1 The confirmed overall response rate (ORR) was 60.7% (95% CI, 47.3%-72.9%), including complete responses in 8.2% of patients, and the disease control rate (DCR) was 90.2% (95% CI, 79.8%-96.3%). The median duration of response (DOR) was 11.1 months (95% CI, 7.6-18.4), and the median PFS was 12.8 months (95% CI, 10.8-18.4). The estimated 12-month overall survival (OS) rate was 76.6% (95% CI, 63.7%-85.4%).

The safety profile was consistent with the known profiles of daraxonrasib and gemcitabine/nab-paclitaxel, and no new safety signals were identified with longer follow-up.

"With longer follow-up and a larger patient population, we are seeing a notable combination of high response rates, including deep complete responses, and durable disease control, with median progression-free survival exceeding one year," Wungki Park, MD, MS, a medical oncologist at the David M. Rubenstein Center for Pancreatic Cancer Research at Memorial Sloan Kettering Cancer Center in New York, New York, and an investigator on RMC-GI-102 and RASolute 303, stated in a news release. "The emerging survival signal is meaningful and is estimated at 76.6% for patients to be alive at 1 year. Taken together, these findings provide a compelling rationale to further evaluate daraxonrasib as a potential first-line treatment option."

What was the rationale for evaluating daraxonrasib plus gemcitabine/nab-paclitaxel in first-line mPDAC?

RAS alterations represent the main driver of pancreatic cancer, and daraxonrasib is an oral, RAS(ON) multi-selective, noncovalent, tri-complex inhibitor. In the earlier analysis of RMC-GI-102 presented at the AACR Annual Meeting, patients treated with daraxonrasib plus gemcitabine and nab-paclitaxel (n = 40) achieved an ORR of 58% (95% CI, 41%-73%) and a DCR of 90% (95% CI, 76%-97%) at a median follow-up of 9.7 months (range, 5.7-13.8).³ The estimated 6-month PFS and OS rates were 84% (95% CI, 68%-93%) and 90% (95% CI, 76%-96%), respectively.

Daraxonrasib monotherapy is approved by the FDA for the treatment of adult patients with mPDAC who have received at least 1 prior systemic therapy or who are not candidates for multiagent systemic therapy, and the European Commission approved it for adult patients with mPDAC who have received at least 1 prior systemic therapy.¹ Both approvals were supported by data from the phase 3 RASolute 302 trial (NCT06625320) in previously treated mPDAC.⁴

What was the design of the phase 1/2 RMC-GI-102 trial?

RMC-GI-102 is an open-label, multicenter, nonrandomized phase 1/2 platform study of RAS(ON) inhibitors in patients with gastrointestinal solid tumors; subprotocol C evaluates daraxonrasib plus gemcitabine and nab-paclitaxel in metastatic PDAC.5 Eligible patients were at least 18 years of age and had pathologically or cytologically documented metastatic pancreatic carcinoma; an ECOG performance status of 0 or 1; adequate organ function; and, in the first-line cohort, no prior treatment for metastatic disease and measurable disease per RECIST 1.1 criteria.3,5

RMC-GI-102 Trial: Key Takeaways

  • Among 61 patients with treatment-naive metastatic pancreatic adenocarcinoma, daraxonrasib plus gemcitabine/nab-paclitaxel produced a confirmed ORR of 60.7%, including complete responses in 8.2% of patients, at a median follow-up of 18.3 months.
  • Median PFS was 12.8 months, and the estimated 12-month OS rate was 76.6%.
  • The phase 3 RASolute 303 trial is comparing daraxonrasib alone or with gemcitabine/nab-paclitaxel vs gemcitabine/nab-paclitaxel alone, regardless of tumor RAS genotype.

Patients in the first-line cohort were eligible regardless of RAS mutation status, including those with RAS wild-type tumors.2 Patients with primary central nervous system tumors, active brain metastases, impaired gastrointestinal function that could alter drug absorption, or major surgery within 28 days of the first dose were excluded.3,5

After dose escalation, the expansion cohort received daraxonrasib at 200 mg orally once daily plus gemcitabine at 1000 mg/m² and nab-paclitaxel at 125 mg/m² on days 1 and 15 of each 28-day cycle.³ For subprotocol C, the primary end points are adverse effects and dose-limiting toxicities; secondary end points include ORR, DOR, DCR, PFS, and OS.⁵

What are the next steps for investigating daraxonrasib in first-line metastatic pancreatic adenocarcinoma?

In September 2026, the FDA granted breakthrough therapy designation to daraxonrasib plus gemcitabine and nab-paclitaxel for patients with treatment-naive mPDAC.¹

The global, randomized, open-label phase 3 RASolute 303 trial plans to enroll 900 patients, regardless of tumor RAS genotype.⁶ Patients are being randomly assigned to 1 of 3 arms:

  • Arm A: daraxonrasib monotherapy
  • Arm B: daraxonrasib plus gemcitabine and nab-paclitaxel
  • Arm C: gemcitabine and nab-paclitaxel alone

Eligible patients are at least 18 years of age and have histologically or cytologically confirmed pancreatic adenocarcinoma; metastatic disease diagnosed no more than 6 weeks before informed consent; documented RAS mutation status, either mutant or wild-type; measurable disease per RECIST 1.1 criteria; an ECOG performance status of 0 or 1; and adequate organ function. Key exclusion criteria include prior systemic anticancer therapy in the metastatic or locally advanced setting; prior RAS-targeted therapy in any setting; active or known untreated central nervous system metastases; and major surgery within 28 days before random assignment.

The primary end points are PFS by blinded independent central review and OS.

“People with treatment-naïve metastatic pancreatic cancer urgently need more effective treatment options, given the limited clinical benefit of current chemotherapy regimens,” Alan Sandler, MD, chief development officer of Revolution Medicines, added in a news release.1 “The FDA’s recent breakthrough therapy designation for [daraxonrasib] plus gemcitabine and nab-paclitaxel in this setting underscores the urgency of this work. The durability of treatment shown with these updated phase 1/2 results is particularly encouraging and supports the ongoing phase 3 RASolute 303 trial, which is evaluating [daraxonrasib] both as a monotherapy and in combination with gemcitabine and nab-paclitaxel vs gemcitabine and nab-paclitaxel alone in patients with treatment-naïve metastatic PDAC, independent of tumor RAS genotype.”

References

  1. Revolution Medicines presents updated phase 1/2 data for Rasonque (daraxonrasib) plus chemotherapy in first-line metastatic pancreatic cancer at ENA 2026. News release. Revolution Medicines, Inc. November 19, 2026. Accessed November 20, 2026. https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-presents-updated-phase-12-data-rasonquer
  2. Park W, Manji GA, Azad NS, et al. Daraxonrasib plus gemcitabine/nab-paclitaxel (GnP) as first-line (1L) treatment for patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC). Eur J Cancer. 2026;248(suppl):117451. doi:10.1016/j.ejca.2026.118149
  3. Wolpin BM, Musher BL, Manji GA, et al. Daraxonrasib plus chemotherapy (CT) as first-line (1L) treatment for patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC). Cancer Res. 2026;86(8 suppl):LB407. doi:10.1158/1538-7445.AM2026-LB407
  4. O'Reilly EM, Wainberg ZA, Hendifar AE, et al; RASolute 302 Trial Investigators. Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer. N Engl J Med. 2026;395(4):325-337. doi:10.1056/NEJMoa2605555
  5. Study of RAS(ON) inhibitors in patients with gastrointestinal solid tumors. ClinicalTrials.gov. Updated September 22, 2026. Accessed November 20, 2026. https://clinicaltrials.gov/study/NCT06445062
  6. Study of daraxonrasib and daraxonrasib + GnP as first-line treatment in patients with metastatic pancreatic adenocarcinoma. ClinicalTrials.gov. Updated November 16, 2026. Accessed November 20, 2026. https://clinicaltrials.gov/study/NCT07491445

Related to this article